Profile data is unavailable for this security.
About the company
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-26.19m
- Incorporated2008
- Employees22.00
- LocationTheriva Biologics Inc9605 Medical Center Drive, Suite 270ROCKVILLE 20850United StatesUSA
- Phone+1 (734) 332-7800
- Fax+1 (734) 332-7878
- Websitehttps://therivabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| enVVeno Medical Corp | 0.00 | -21.97m | 6.68m | 37.00 | -- | 0.1999 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Biomx Inc | 0.00 | -36.20m | 6.81m | 20.00 | -- | -- | -- | -- | -23.69 | -23.69 | 0.00 | -0.817 | 0.00 | -- | -- | 0.00 | -147.70 | -62.93 | -210.64 | -78.33 | -- | -- | -- | -- | -- | -41.56 | -- | -- | -- | -- | -104.20 | -- | -71.20 | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.88m | 1.00 | -- | 0.2679 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Pulmatrix Inc | 0.00 | -5.16m | 6.90m | 2.00 | -- | 1.81 | -- | -- | -1.41 | -1.41 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -73.31 | -41.17 | -80.51 | -46.40 | -- | -- | -- | -257.55 | -- | -- | 0.00 | -- | -100.00 | -- | 46.00 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -2.34m | 6.99m | 6.00 | -- | 0.7152 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 7.07m | 37.00 | -- | 0.3128 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -26.19m | 7.09m | 22.00 | -- | 0.3039 | -- | -- | -5.53 | -5.53 | 0.00 | 0.6539 | 0.00 | -- | -- | 0.00 | -73.83 | -37.94 | -99.55 | -42.02 | -- | -- | -- | -- | -- | -- | 0.2025 | -- | -- | -- | -39.81 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -8.98m | 7.14m | 2.00 | -- | 0.1343 | -- | -- | -1.32 | -1.32 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -12.74 | 7.21 | -13.51 | 7.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 235.53 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.58m | -11.29m | 7.15m | 16.00 | -- | 0.4979 | -- | 2.00 | -15.13 | -15.13 | 4.65 | 8.96 | 0.272 | 2.98 | 9.91 | 223,832.50 | -86.08 | -73.55 | -132.01 | -123.30 | 46.21 | -- | -316.50 | -476.22 | 2.26 | -241.14 | 0.0012 | -- | -1.90 | 74.49 | -4.06 | -- | -- | -- |
| Aspire Biopharma Holdings Inc | 1.94k | -28.70m | 7.29m | -- | -- | -- | -- | 3,755.16 | -65.96 | -65.96 | 0.0022 | -9.26 | 0.0004 | -- | -- | -- | -633.21 | -- | -- | -- | 45.36 | -- | -1,479,598.00 | -- | 0.1708 | -6.20 | -- | -- | -- | -- | -380.85 | -- | -- | -- |
| Calcimedica Inc | 0.00 | -23.06m | 7.30m | 14.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0188 | 0.00 | -- | -- | 0.00 | -148.18 | -58.12 | -194.91 | -64.99 | -- | -- | -- | -- | -- | -- | 1.03 | -- | -- | -- | 60.12 | -- | -57.90 | -- |
| TRON Group Inc | 1.01m | -549.47k | 7.38m | 50.00 | -- | -- | -- | 7.31 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 7.41m | 1.00 | -- | 2.61 | -- | 1,234.95 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 241.78k | 0.68% |
| Geode Capital Management LLCas of 31 Dec 2025 | 212.09k | 0.59% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 200.00k | 0.56% |
| UBS Securities LLCas of 31 Dec 2025 | 191.41k | 0.54% |
| Ikarian Capital LLCas of 31 Dec 2025 | 112.08k | 0.31% |
| Two Sigma Securities LLCas of 31 Dec 2025 | 42.89k | 0.12% |
| Two Sigma Investments LPas of 31 Dec 2025 | 42.34k | 0.12% |
| DRW Securities LLCas of 31 Dec 2025 | 41.75k | 0.12% |
| XTX Markets LLCas of 31 Dec 2025 | 39.45k | 0.11% |
| StoneX Group, Inc. (Investment Management)as of 31 Dec 2025 | 37.22k | 0.10% |
